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Abstract— Following the tradition established at previous 
IEEE INES conferences, this paper presents the results 
achieved by the Physiological Controls Group of Óbuda 
University in the field of physiological control last year 
(2013). The application target was focused on diabetes 
(artificial pancreas), tumor (antiangiogenic therapy), and 
hemodialysis (control of peristaltic pumps). 
I. INTRODUCTION 
Physiological control studies and applies identification 
and control strategies in order to understand and help 
automated treatment of various diseases or injuries of the 
human body. As a particular field of biomedical 
engineering [1], nowadays the key target of physiological 
control is to efficiently create and support personalized 
solutions for disease management in a model-based way. 
The aim of the recently established Physiological Controls 
Group of the Óbuda University is to develop solutions in 
the mentioned area working together in control 
applications with the Department of Control Engineering 
and Information Technology of the Budapest University 
of Technology and Economics and the Semmelweis 
University from Budapest. 
The article briefly summarizes the newest (last year, 
2013) results obtained in the field, following the tradition 
established at the previous IEEE INES 2011-2013 
conferences [2-4]. Control results in three different fields 
are presented: 
• cancer, where the uncontrolled growth of 
abnormal cells [5] are proposed to be handled by 
control engineering methods. As a result, not 
only the tumor volume can be minimized, but 
also the dosage of the inhibitor creating a cost-
efficient therapy. For this our idea follows robust 
control methodology. 
• diabetes mellitus, where the problem of artificial 
pancreas [6] is investigated. Newest results in 
robust control are presented in order to deal with 
high uncertainties caused by imprecise 
descriptions of the glucose metabolism. 
• hemodialysis, where direct blood particle separa-
tion is done with external devices, i.e. peristaltic 
pumps maintain the fluid flows [7]. However, the 
transfer depends on their loaded tube segment; 
hence, the fluid balance should be controlled. 
II. ROBUST CONTROL DEVELOPMENT FOR CANCER 
TREATMENT 
P. Hahnfeldt et al. created a dynamic model for tumor 
growth for antiangiogenic therapy [8]. The aim of 
antiangiogenic therapy is to prevent tumors from forming 
new blood vessels, because without angiogenesis tumor 
growth is inhibited [9]. The original model was modified; 
the simplified model takes into account continuous 
infusion therapy [10]. Fig. 1 presents the simulated tumor 
growth with and without antiangiogenic therapy. Without 
treatment the growing tumor size reaches lethal state 
(17340 mm3), while with antiangiogenic therapy the 
tumor size can be reduced. 
Hence, robust control strategy has been investigated. 
The proposed control structure is presented in Fig. 2. K is 
the two-degrees of freedom controller which consists of 
two parts: Kr is the feedforward branch and Ky is the 
feedback branch. Multiplicative uncertainty (Gunc) has 
been taken into account in order to handle differences 
between the nominal model and the real system. 
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Figure 1. Simulation results of with and without therapy case. 
 
Figure 2. The closed-loop interconnection structure for controller 
design 
Wn stands for sensor noise weighting function, Wu for 
the control input one, while Tid represents the transfer 
function for the ideal system. Wperf represents the 
performance weighting function [11]. 
The results (Fig. 3 and Fig. 4) have shown that the 
designed H∞ controller can handle the sensor noise in a 
robust way until 15%. We have simulated and 
compared the changes in three different cases. The 
first case was a therapy when the inhibitor was 
administered by the H∞ controller. In the second case the 
therapy was based on the Hungarian OEP protocol 
for antiangiogenic monotherapy [12].The third case 
was the simulation without therapy. 
One can see that intermittent dosing used by the 
chemotherapy protocol is not effective. The tumor volume 
reduced slightly as a result of one-day dose, but between 
the treatment phases, tumor grows back again. At the end 
of the whole treatment period, there is no large difference 
between the therapy with OEP protocol and the case 
without therapy. 
 
III. ROBUST CONTROL FRAMEWORK FOR TYPE 1 
DIABETES 
Although model predictive control (MPC) is one of the 
most effective method in individual based therapies of 
diabetes, in practice the controlled process can deviate 
from the nominal model. Hence, robust methods are 
required in order to satisfy general requirements (e.g. 
avoiding hypoglycemia) under unexpected situations or 
extreme conditions. 
Our approach focuses on Linear Parameter Varying 
(LPV) method [13] making direct nonlinear control 
possible. In the last period, we have examined whether the 
capabilities of a robust LPV controller could be extended 
by additional constraints. Investigations have been done 
for the well-known model of [14]. 
 
  
Figure 3. Comparison of input and output signals of the systems in the mentioned cases: (i), (ii) and (iii) 
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Figure 4. Comparison of changes in tumor volume after making the diagnosis (14137 mm3) in three different cases: 
a) therapy using the controller which was designed with Robust Control method 
b) therapy based on the Hungarian OEP protocol for antiangiogenic monotherapy 
c) without therapy 
There are two main sources of uncertainty: parameter 
inaccuracy and scheduling parameter inaccuracy. Fig. 5 
captures the control structure taken into account. 
Measurement noise and the parameter inaccuracies 
were randomized and the aim of our research was to 
examine control quality in case of unannounced meals 
or high amount of carbohydrate (CHO) intakes. 
An example of virtual patient simulation is shown 
in Fig. 6. Three different protocols have been taken 
into account: classical 150 g CHO, 215 g CHO and 
irregular and inexactly determined (±20 g CHO) 
meal intake. Overall summary of the investigations 
have been presented on the well-known literature 
metric of control variability grid analysis (CVGA) 
(Figs. 7-8). 
One can see that robustness is achieved even in 
extreme conditions, demonstrating the effectiveness 
of the methodology avoiding hypoglycaemia as well. 
 
 
Figure 5. Control structure for type 1 diabetes investigations 
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Figure 6. Example for Virtual Patient (VP) simulation 
 
IV. AUTOMATIC CONTROL OF PERISTALTIC PUMPS 
The transfer volume of peristaltic pumps depends 
mainly on their loaded tube segment. Due to the deviation 
of production their transfer volume can differ by ±10% 
that is important from the patient point of view. As a 
result, fluid flow should be controlled automatically. The 
system contains a hanged bag above the peristaltic pump's 
level (with the solution to be transported), the peristaltic 
pump and a vessel collecting the transported fluid. 
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Figure 7. CVGA of all LPV controllers for 150 g of daily carbohydrate 
intake 
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Figure 8. CVGA of all LPV controllers for (2) meal intake protocol 
 
First system identification was necessary in order to 
determine the transfer function of the considered plant. 
Different methods have been used and compared: ARX, 
ARMAX, Box-Jenkins and output error (OE). 
 
Figure 9. System error from settling time point of view (At 300 ml/h, -
10% slope error, 20 g offset error) 
Two control methodologies have been examined: 
classical PID and fuzzy rule-based ones. Three scenarios 
were taken into account with different fluid flows: one 
with medium low flow (300 ml/h), one with medium flow 
(1500 ml/h) and one with highest flow (3000 ml/h). 
Control quality from settling time, accuracy and overshoot 
can be seen in Fig. 9, Fig. 10 and Fig. 11. 
Due to similar results obtained, PID controller was 
applied for the real system (Fig. 12). It can be seen that 
desired performance was achieved. 
 
Figure 10. System error from overshot point of view (At 1500 ml/h, -
10% slope error, 20 g offset error) 
 
Figure 11. System error at in accuracy examination  
(At 3000 ml/h, -10% slope error, 20 g offset error) 
 
 
Figure 12. System error in the real system 
(At 1000 ml/h, -5% slope error 20 g offset error) 
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V. CONCLUSIONS 
The paper summarized the latest research results in the 
field of physiological modeling and control carried out by 
Physiological Controls Group of the Óbuda University. 
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